125 related articles for article (PubMed ID: 19689485)
1. Where now for insulin glargine--a time for pragmatic medicine?
Thomson GA; Craig R
Int J Clin Pract; 2009 Oct; 63(10):1413-5. PubMed ID: 19689485
[No Abstract] [Full Text] [Related]
2. Insulin glargine (Lantus) and cancer risk.
Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
[No Abstract] [Full Text] [Related]
3. Putting insulin glargine and malignancies into perspective.
Ehninger G; Schmidt AH
Oncologist; 2009 Dec; 14(12):1169-74. PubMed ID: 20007644
[No Abstract] [Full Text] [Related]
4. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk in diabetic patients treated with insulin glargine?
Prescrire Int; 2010 Aug; 19(108):162-3. PubMed ID: 20939447
[TBL] [Abstract][Full Text] [Related]
6. Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism?
Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
Diabet Med; 2011 Mar; 28(3):276-86. PubMed ID: 21309835
[TBL] [Abstract][Full Text] [Related]
7. Insuline glusine (Apidra): a new rapid-acting insulin.
Med Lett Drugs Ther; 2006 Apr; 48(1233):33-4. PubMed ID: 16625142
[TBL] [Abstract][Full Text] [Related]
8. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
Edwards KL; Riche DM; Stroup JS; Goldman-Levine JD; Padiyara RS; Cross LB; Kane MP
Pharmacotherapy; 2010 Sep; 30(9):955-65. PubMed ID: 20795850
[TBL] [Abstract][Full Text] [Related]
9. [Type 2 diabetes: explosive issues in routine care].
Aumiller J
MMW Fortschr Med; 2009 Oct; 151(42):20. PubMed ID: 19938775
[No Abstract] [Full Text] [Related]
10. [Analog insulin requirements of the average patient. Interview by Dr. rer. nat. Anita Schweiger].
Renner MR
Fortschr Med; 1997 Apr; 115(10):8-10. PubMed ID: 9206690
[No Abstract] [Full Text] [Related]
11. Insulin glargine: a long-acting insulin for diabetes mellitus.
Garces K
Issues Emerg Health Technol; 2003 Nov; (52):1-4. PubMed ID: 14626260
[TBL] [Abstract][Full Text] [Related]
12. Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus.
Dixon AN; Bain SC
BMJ; 2005 Feb; 330(7489):455. PubMed ID: 15731143
[No Abstract] [Full Text] [Related]
13. Insulin glargine: cornerstone treatment for type 2 diabetes patients. Introduction.
Garg SK
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():1-4. PubMed ID: 18577151
[No Abstract] [Full Text] [Related]
14. An update on the long-acting insulin analogue glargine.
Thisted H; Johnsen SP; Rungby J
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
[TBL] [Abstract][Full Text] [Related]
15. Insulin glargine for type 2 diabetes.
Hemraj F; Garces K
Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441
[TBL] [Abstract][Full Text] [Related]
16. Insulin glulisine. Aventis Pharma.
Barlocco D
Curr Opin Investig Drugs; 2003 Oct; 4(10):1240-4. PubMed ID: 14649217
[TBL] [Abstract][Full Text] [Related]
17. [Cancer more common in diabetes. Maybe the treatment itself also plays a role].
Nilsson PM; Eliasson B
Lakartidningen; 2010 Jan 27-Feb 2; 107(4):170-1. PubMed ID: 20333969
[No Abstract] [Full Text] [Related]
18. Refining basal insulin therapy: what have we learned in the age of analogues?
Devries JH; Nattrass M; Pieber TR
Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
[TBL] [Abstract][Full Text] [Related]
19. Insulin aspart: a review.
Owens D; Vora J
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):793-804. PubMed ID: 17014395
[TBL] [Abstract][Full Text] [Related]
20. [Syndrome of chronic overdose of insulin and hypoglycemic sulfanilamide drugs].
Arzumetova DS; Saburenko MB; Shagazatova BKh; Zabikhodzhaeva GZ
Klin Med (Mosk); 1989 Apr; 67(4):99-101. PubMed ID: 2666739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
